As with all weight loss medications, there are side effects
The REWIND study evaluated the cardiovascular safety of dulaglutide (1.5 mg) in comparison to placebo ( Exenatide The EXSCEL (Exenatide Study of Cardiovascular Event Lowering) trial evaluated the CV safety of exenatide (2 mg weekly)
Our NGO is registered under Section 80G of the Income Tax Act, India.
Originally studied for its ability to support gut health, research has expanded to explore its impact on a wide range of tissuesmuscle, tendon, nervous system, and even the cardiovascular system
To consult our professionals, please contact us or book an appointment online
The Jupiter study is part of an international collaboration for Webbs Early Release Science program